Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2025)

Ultragenyx Pharmaceutical has reported Tax Provisions over the past 9 years, most recently at $870000.0 for Q4 2025.

  • Quarterly Tax Provisions fell 37.14% to $870000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 33.33% year-over-year, with the annual reading at $4.0 million for FY2025, 33.33% up from the prior year.
  • Tax Provisions was $870000.0 for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $873000.0 in the prior quarter.
  • Over five years, Tax Provisions peaked at $6.3 million in Q3 2022 and troughed at -$3.9 million in Q4 2023.
  • The 5-year median for Tax Provisions is $526500.0 (2022), against an average of $669000.0.
  • Year-over-year, Tax Provisions skyrocketed 3354.4% in 2022 and then crashed 2151.32% in 2023.
  • A 5-year view of Tax Provisions shows it stood at $20000.0 in 2021, then surged by 845.0% to $189000.0 in 2022, then crashed by 2151.32% to -$3.9 million in 2023, then soared by 135.7% to $1.4 million in 2024, then plummeted by 37.14% to $870000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Tax Provisions are $870000.0 (Q4 2025), $873000.0 (Q3 2025), and $947000.0 (Q2 2025).